Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,otherLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,otherCashflowsFromFinancingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ITRM,31517000.0,179139008,2451000,,-98861000,,-98921000,3396000,0,-5847000,-5847000,,-2952000,,,,60000,0,5847000,0,-93014000,,-98921000,-98921000,415580000.0,83648000.0,31517000.0,32610000.0,115165000.0,1787000.0,125000.0,-385850000.0,5293000.0,66640000.0,43809000.0,6621000.0,5639000.0,104233000.0,36135000.0,806000.0,34892000.0,1853000.0,,-33920000.0,1037000.0,-33920000.0,-1629000.0,86982000.0,3153000.0,88611000.0,51924000.0,-6000.0,-1132000.0,35000.0,91132000.0,,,60424000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.24029997,0.5328159,0.451 - 2.995,-2.3037,-0.76918197,0.451,2.995,1620995400,1628080200,1628512200,-2.66,-0.36,-0.28,3.1790984,0.665 - 0.7178,0.67,0.0,0.0,11,8,finmb_318354064,NasdaqCM,Iterum Therapeutics plc,USD,12350982,3117871,-2.4689286,0.176,0.8156286,-0.12432861,-0.15243287,1.3301232,-0.6388232,-0.48027372,124454736,-1.9202776,3.9278407,15,America/New_York,EDT,-14400000,4,-0.0022999644,-0.33270136,1630576177,0.689,NCM,PRE,us_market,Iterum Therapeutics plc,0.6913,1630526402,0.021299958,0.6605,0.7178,0.665,3552153,1.25,,,2.995,0.451,0.8156,1.3301,12.35M,3.12M,179.14M,,176.16M,0.59%,9.58%,2.91M,0.33,1.71%,1.63%,3.55M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.91%,,,,,,-24.92M,-134.83M,-2.6600,,102.78M,0.57,47.11M,149.47,2.38,0.18,-28.27M,-12.46M,Value,2,Healthcare,7,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.",Dublin,353 1 903 8920,1609372800,Ireland,http://www.iterumtx.com,86400,Harcourt Centre,Biotechnology,"Block 2, Floor 3 Harcourt Street"
t-1,ITRM,-50559000.0,179139008,2351000,,-11162000,,-11186000,2293000,0,-4644000,-4644000,,-4207000,,,,24000,0,4644000,0,-6518000,,-11186000,-11186000,235876000.0,83351000.0,-50559000.0,31992000.0,32792000.0,494000.0,217000.0,-286929000.0,5638000.0,14508000.0,41698000.0,6488000.0,5682000.0,21472000.0,2360000.0,3741000.0,35851000.0,816000.0,630000.0,-33920000.0,-1792000.0,-33920000.0,-1578000.0,15127000.0,-2446000.0,5111000.0,6120000.0,24000.0,-9031000.0,39000.0,3274000.0,11594000.0,,-20226000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.24029997,0.5328159,0.451 - 2.995,-2.3037,-0.76918197,0.451,2.995,1620995400,1628080200,1628512200,-2.66,-0.36,-0.28,3.1790984,0.665 - 0.7178,0.67,0.0,0.0,11,8,finmb_318354064,NasdaqCM,Iterum Therapeutics plc,USD,12350982,3117871,-2.4689286,0.176,0.8156286,-0.12432861,-0.15243287,1.3301232,-0.6388232,-0.48027372,124454736,-1.9202776,3.9278407,15,America/New_York,EDT,-14400000,4,-0.0022999644,-0.33270136,1630576177,0.689,NCM,PRE,us_market,Iterum Therapeutics plc,0.6913,1630526402,0.021299958,0.6605,0.7178,0.665,3552153,1.25,,,2.995,0.451,0.8156,1.3301,12.35M,3.12M,179.14M,,176.16M,0.59%,9.58%,2.91M,0.33,1.71%,1.63%,3.55M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.91%,,,,,,-24.92M,-134.83M,-2.6600,,102.78M,0.57,47.11M,149.47,2.38,0.18,-28.27M,-12.46M,Value,2,Healthcare,7,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.",Dublin,353 1 903 8920,1609372800,Ireland,http://www.iterumtx.com,86400,Harcourt Centre,Biotechnology,"Block 2, Floor 3 Harcourt Street"
t-2,ITRM,-55903000.0,179139008,3937000,,-11779000,,-12199000,2398000,0,-6335000,-6335000,,-4183000,,,,420000,0,6335000,0,-5444000,,-12199000,-12199000,219628000.0,82173000.0,-55903000.0,29111000.0,26270000.0,212000.0,794000.0,-275743000.0,7012000.0,8570000.0,40866000.0,6158000.0,7199000.0,12059000.0,1334000.0,757000.0,34145000.0,2645000.0,630000.0,-33920000.0,361000.0,-9000.0,-1552000.0,767000.0,1278000.0,2319000.0,-3661000.0,-2000.0,-4417000.0,44000.0,3389000.0,11594000.0,-9000.0,-28807000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.24029997,0.5328159,0.451 - 2.995,-2.3037,-0.76918197,0.451,2.995,1620995400,1628080200,1628512200,-2.66,-0.36,-0.28,3.1790984,0.665 - 0.7178,0.67,0.0,0.0,11,8,finmb_318354064,NasdaqCM,Iterum Therapeutics plc,USD,12350982,3117871,-2.4689286,0.176,0.8156286,-0.12432861,-0.15243287,1.3301232,-0.6388232,-0.48027372,124454736,-1.9202776,3.9278407,15,America/New_York,EDT,-14400000,4,-0.0022999644,-0.33270136,1630576177,0.689,NCM,PRE,us_market,Iterum Therapeutics plc,0.6913,1630526402,0.021299958,0.6605,0.7178,0.665,3552153,1.25,,,2.995,0.451,0.8156,1.3301,12.35M,3.12M,179.14M,,176.16M,0.59%,9.58%,2.91M,0.33,1.71%,1.63%,3.55M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.91%,,,,,,-24.92M,-134.83M,-2.6600,,102.78M,0.57,47.11M,149.47,2.38,0.18,-28.27M,-12.46M,Value,2,Healthcare,7,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.",Dublin,353 1 903 8920,1609372800,Ireland,http://www.iterumtx.com,86400,Harcourt Centre,Biotechnology,"Block 2, Floor 3 Harcourt Street"
t-3,ITRM,-48789000.0,179139008,5043000,,-12343000,,-12521000,3210000,0,-8253000,-8253000,,-4075000,,,,178000,0,8253000,0,-4090000,,-12521000,-12521000,214576000.0,80476000.0,-48789000.0,27909000.0,31687000.0,179000.0,3139000.0,-263544000.0,6222000.0,12250000.0,40616000.0,5983000.0,7389000.0,18076000.0,1278000.0,824000.0,32757000.0,2246000.0,630000.0,-33920000.0,-4055000.0,-2000.0,-807000.0,2710000.0,-2639000.0,3517000.0,-10990000.0,-9000.0,-13689000.0,39000.0,2203000.0,11594000.0,-2000.0,-22540000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.24029997,0.5328159,0.451 - 2.995,-2.3037,-0.76918197,0.451,2.995,1620995400,1628080200,1628512200,-2.66,-0.36,-0.28,3.1790984,0.665 - 0.7178,0.67,0.0,0.0,11,8,finmb_318354064,NasdaqCM,Iterum Therapeutics plc,USD,12350982,3117871,-2.4689286,0.176,0.8156286,-0.12432861,-0.15243287,1.3301232,-0.6388232,-0.48027372,124454736,-1.9202776,3.9278407,15,America/New_York,EDT,-14400000,4,-0.0022999644,-0.33270136,1630576177,0.689,NCM,PRE,us_market,Iterum Therapeutics plc,0.6913,1630526402,0.021299958,0.6605,0.7178,0.665,3552153,1.25,,,2.995,0.451,0.8156,1.3301,12.35M,3.12M,179.14M,,176.16M,0.59%,9.58%,2.91M,0.33,1.71%,1.63%,3.55M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.91%,,,,,,-24.92M,-134.83M,-2.6600,,102.78M,0.57,47.11M,149.47,2.38,0.18,-28.27M,-12.46M,Value,2,Healthcare,7,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.",Dublin,353 1 903 8920,1609372800,Ireland,http://www.iterumtx.com,86400,Harcourt Centre,Biotechnology,"Block 2, Floor 3 Harcourt Street"
